Advanced search
Publication Cover
Future Oncology Volume 19, 2023 - Issue 15
Submit an article Journal homepage
147
Views
0
CrossRef citations to date
0
Altmetric
Clinical Trial Protocol

Gemcitabine and cisplatin or oxaliplatin chemotherapy combined with atezolizumab plus bevacizumab for advanced biliary tract cancers: a single-arm trial

Kang Wang1 Department of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital,Naval Medical University, Shanghai, 200433, ChinaView further author information
,
Hong-Ming Yu1 Department of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital,Naval Medical University, Shanghai, 200433, ChinaView further author information
,
Yan-Jun Xiang1 Department of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital,Naval Medical University, Shanghai, 200433, ChinaORCID Iconhttps://orcid.org/0000-0002-7378-6724View further author information
ORCID Icon,
Yu-Qiang Cheng1 Department of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital,Naval Medical University, Shanghai, 200433, ChinaView further author information
,
Qian-Zhi Ni1 Department of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital,Naval Medical University, Shanghai, 200433, China;2 CAS Key Laboratory of Nutrition, Metabolism & Food Safety, Shanghai Institute of Nutrition & Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, 200031, ChinaView further author information
,
Wei-Xing Guo1 Department of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital,Naval Medical University, Shanghai, 200433, ChinaView further author information
,
Jie Shi1 Department of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital,Naval Medical University, Shanghai, 200433, ChinaView further author information
,
Shuang Feng3 Department of Radiotherapy, Eastern Hepatobiliary Surgery Hospital,Naval Medical University, Shanghai, 200433, ChinaView further author information
,
Jian Zhai4 Department II of Interventional Radiology, Eastern Hepatobiliary Surgery Hospital,Naval Medical University, Shanghai, 200433, ChinaView further author information
&
Shu-Qun Cheng1 Department of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital,Naval Medical University, Shanghai, 200433, ChinaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-6098-8028View further author information
ORCID Icon show all
Pages 1029-1035 | Received 22 Feb 2023, Accepted 07 Mar 2023, Published online: 03 May 2023

References

  • Tella SH , KommalapatiA, BoradMJ, MahipalA. Second-line therapies in advanced biliary tract cancers. Lancet Oncol.21(1), e29–e41 (2020).
  • Fitzmaurice C , Abate D, Abbasi Net al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the Global Burden of Disease Study. JAMA Oncol.5(12), 1749–1768 (2019).
  • Everhart JE , RuhlCE. Burden of digestive diseases in the United States part III: liver, biliary tract, and pancreas. Gastroenterology136(4), 1134–1144 (2009).
  • Valle J , WasanH, PalmerDHet al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N. Engl. J. Med.362(14), 1273–1281 (2010).
  • Andre T , TournigandC, RosmorducOet al. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann. Oncol.15(9), 1339–1343 (2004).
  • Valle JW , WasanH, LopesAet al. Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial. Lancet Oncol.16(8), 967–978 (2015).
  • Valle JW , VogelA, DenlingerCSet al. Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 study. Lancet Oncol.22(10), 1468–1482 (2021).
  • Garcia J , HurwitzHI, SandlerABet al. Bevacizumab (Avastin®) in cancer treatment: a review of 15 years of clinical experience and future outlook. Cancer Treat. Rev.86, 102017 (2020).
  • Zhu AX , MeyerhardtJA, BlaszkowskyLSet al. Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study. Lancet Oncol.11(1), 48–54 (2010).
  • Chen X , WuX, WuHet al. Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial. J. Immunother. Cancer8(2), e001240 (2020).
  • Kim RD , ChungV, AleseOBet al. A phase 2 multi-institutional study of nivolumab for patients with advanced refractory biliary tract cancer. JAMA Oncol.6(6), 888–894 (2020).
  • Feng K , LiuY, ZhaoYet al. Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: results from a phase II study. J. Immunother. Cancer8(1), e000367 (2020).
  • Monge C , PehrssonEC, XieCet al. A phase II study of pembrolizumab in combination with capecitabine and oxaliplatin with molecular profiling in patients with advanced biliary tract carcinoma. Oncologist27(3), e273–e285 (2022).
  • Oh D-Y , HeAR, QinSet al. A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1. J. Clin. Oncol.40(Suppl. 4), S378 (2022).
  • Finn RS , QinS, IkedaMet al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N. Engl. J. Med.382(20), 1894–1905 (2020).
  • Benson AB , D’angelicaMI, AbbottDEet al. Hepatobiliary cancers, version 2.2021, NCCN clinical practice guidelines in oncology. J. Natl Compr. Canc. Netw.19(5), 541–565 (2021).
  • Fiteni F , NguyenT, VernereyDet al. Cisplatin/gemcitabine or oxaliplatin/gemcitabine in the treatment of advanced biliary tract cancer: a systematic review. Cancer Med.3(6), 1502–1511 (2014).
  • Hack SP , VerretW, MullaSet al. IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer. Ther. Adv. Med. Oncol.13, 17588359211036544 (2021).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.